Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: A review

European Journal of Cardio-thoracic Surgery

Volumn 13, Issue 1, 1998, Pages 1-12

  Vansteenkiste, Johan ^a   De Leyn, Paul ^a   Deneffe, Georges ^a   Menten, Johan ^a   Lerut, Tony ^a   Demedts, Maurits ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Combined modality treatment; Induction chemotherapy; Lung surgery; N2 disease; Non small cell lung carcinoma

Indexed keywords

CISPLATIN; MITOMYCIN C;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0031890240     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(97)00267-4     Document Type: Review

References (72)

1. Deneffe G., Stalpaert G. Five year survival in resected T3/N2 lung cancer. Acta Chir Belg. 89:1989;159-160.
2. Goldstraw P., Mannam G., Kaplan D., Michael P. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg. 107:1994;19-28.
3. Maggi G. Results of radical treatment of stage IIIa non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 2:1988;329-335.
4. Patterson G.A., Piazza D., Pearson F.et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg. 43:1987;155-159.
5. Pearson F., DeLarue N., Ilves R., Todd T., Cooper J. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 83:1982;1-11.
6. De Leyn P., Deneffe G., Van Raemdonck D., Coosemans W., Vansteenkiste J., Lerut T. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 Disease). Eur J Cardiothorac Surg. 10:1996;649-655.
7. Klastersky J., Burkes R., Choi N.C.et al. Induction therapy for NSCLC: a consensus report. Lung Cancer. 7:1991;15-17.
8. Cybulski I., Lanza L., Bernadette R., Putnam J., McMurtrey M., Roth J. Prognostic significance of computed tomography in resected N2 lung cancer. Ann Thorac Surg. 54:1992;533-537.
9. Martini N., Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am. 67:1987;1037-1049.
10. Goldstraw P. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax. 47:1992;1-3.
11. Kumar P., Herndon J., Langer M.et al. Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2). Cancer. 77:1996;2393-2399.
12. Shepherd F.A. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 55:1993;1585-1592.
13. Sugarbaker D.J., Herndon J., Kohman L.J., Krasna M.J., Green M.R. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg. 109:1995;473-483.
14. Burkes R., Ginsberg R.J., Shepherd F.A.et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol. 10:1992;580-586.
15. Martini N., Kris M.G., Flehinger B.et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 55:1993;1365-1374.
16. Elias A.D., Skarin A.T., Gonin R.et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol. 17:1994;26-36.
17. Pujol J.L., Hayot M., Rouanet P., Le Chevalier T., Michel F.B. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer. Chest. 106:1994;1451-1455.
18. Ciriaco P., Rendina E.A., Venuta F.et al. Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results. Eur J Cardiothorac Surg. 9:1995;305-309.
19. Takita H., Blumenson L.E., Raghavan D. Neoadjuvant chemotherapy of stage III-A and B lung carcinoma using the PACCO regimen. J Surg Oncol. 59:1995;147-150.
20. Darwish S., Minotti V., Crino L.et al. A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer. Lung Cancer. 12:1995;71S-78S.
21. Raut Y., Huu N., Clavier J., Guillerm D., Barra J.A. Surgery and chemotherapy. A new method of treatment for squamous cell bronchial carcinoma. J Thorac Cardiovasc Surg. 88:1984;754-757.
22. Vokes J. Neoadjuvant vindesine, etoposide and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase II study. Chest. 96:1989;110-113.
23. Albain K.S., Rusch V.W., Crowley J.J.et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 13:1995;1880-1892.
24. Mathisen D.J., Wain J.C., Wright C.et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 111:1996;123-131.
25. Rice T.W., Adelstein D.J., Koka A.et al. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg. 60:1995;586-591.
26. Wagner W., von Eiff M., Klinke F., Micke O., Rube C., Willich N. Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study. Strahlenther Onkol. 171:1995;390-397.
27. Weitberg A.B., Yashar J., Glicksman A.S.et al. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. Eur J Cancer. 29A:1993;511-515.
28. Strauss G.M., Herndon J.E., Sherman D.D.et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol. 10:1992;1237-1244.
29. Eagan R.T., Ruud C., Lee R.E., Pairolero P.C., Gail M.H. Pilot study of induction therapy with cyclophosphamide, doxorubicin, cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep. 71:1987;895-900.
30. Skarin A., Jochelson M., Sheldon T.et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol. 40:1989;266-274.
31. Weiden P.L., Piantadosi S. Preoperative chemotherapy and radiation therapy in stage III non-small cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst. 83:1991;266-272.
32. Faber L.P., Kittle C.F., Warren W.H.et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 47:1989;669-675.
33. Palazzi M., Cataldo I., Gramaglia A., De Toma D., Milani F., Ravasi G. Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 27:1993;621-625.
34. Langer C.J., Curran W.J.J., Keller S.M.et al. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 26:1993;469-478.
35. Pisch J., Berson A.M., Malamud S., Beattie E.J., Harvey J., Vikram B. Chemoradiation in advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 33:1995;183-188.
36. Deutsch M., Crawford J., Leopold K.et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer. 74:1994;1243-1252.
37. Rosell R., Gomez Codina J., Camps C.et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl J Med. 330:1994;153-158.
38. Roth J., Fossella F., Komaki R.P.et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non small cell lung cancer. J Natl Cancer Inst. 86:1994;673-680.
39. Pass H.I., Pogrebniak H.W., Steinberg S.M., Mulshine J., Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 53:1992;992-998.
40. Douple E.B., Richmond R.C. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys. 8:1982;501-503.
41. Kish J., Dreilichman A., Jacobs J.et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment of advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep. 66:1982;471-474.
42. Schabel F.M., Trader M.W., Laster W.R., Corbett T.H., Griswald D.P. Cisdichlorodiammineplatinum. Combination of chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 63:1979;1459-1473.
43. Byfield J.E., Stanton W., Sharp T.R., Frankel S.S., Koziol J. Phase I-II study of 120-hour infused 5-FU and split course radiation therapy in localized non-small cell lung cancer. Cancer Treat Rep. 67:1983;933-936.
44. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
45. Goldie J. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol. 14:1987;1-7.
46. Vansteenkiste JF, De Leyn PR, Deneffe GJ et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997;36:1441-50.
47. Glazer G.M., Orringer M., Gross B., Quint L.E. The mediastinum in non-small cell lung cancer: CT-surgical correlation. Am J Roentgenol. 142:1984;1101-1105.
48. Dillemans B., Deneffe G., Verschakelen J., Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardiothorac Surg. 8:1994;37-42.
49. De Leyn P, Cuypers P, Deneffe G et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer in the absence of enlarged nodes on CT scan. Eur J Cardiothorac Surg 1997;12:706-12.
50. Satoh H., Yano H., Ishikawa H., Hasegawa H. Disease extent and response to chemotherapy in non-small cell lung cancer. Acta Oncol. 35:1996;106-107.
51. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 96:1988;440-447.
52. McCaughan B.C. Primary lung cancer invading the chest wall. Surg Clin North Am. 4:1994;17-28.
53. Piehler J.M., Pairolero P.C., Wieland L.H., Offord K.P., Payne W.S., Bernatz P.E. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en-bloc resection. Ann Thorac Surg. 34:1982;684-691.
54. Fleck J., Camargo J., Godoy D.et al. Chemoradiation therapy versus chemotherapy alone as neo-adjuvant treatment for stage III non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol. 12:1993;333.
55. Ratto G.B., Mereu C., Motta G. The prognostic significance of preoperative assessment of mediastinal lymph nodes in patients with lung cancer. Chest. 93:1988;807-813.
56. Watanabe Y., Shimizu J., Oda M.et al. Aggressive surgical intervention in N2 non-small cell lung cancer of the lung. Ann Thorac Surg. 51:1991;253-261.
57. Pisters K.M., Kris M.G., Gralla R.J., Zaman M.B., Heelan R.T., Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol. 11:1993;1757-1762.
58. Buzdar A.U., Legha S.S., Luna M.A., Tashima C.K., Hortobagyi G.N., Blumenschein G.R. Pulmonary toxicity of mitomycin. Cancer. 45:1980;236-244.
59. Rao S.X., Ramaswamy G., Levin M., McCravey J.W. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med. 145:1985;1905-1907.
60. Orwoll E.S., Kiessling P.S., Patterson J.R. Interstitial pneumonia from mitomycin. Ann Intern Med. 89:1978;352-355.
61. Gunstream S.R., Seidenfeld J.J., Sobonya R.E., McMahon L.J. Mitomycin-associated lung disease. Cancer Treat Rev. 67:1983;301-304.
62. McCarthy J.T., Staats B.A. Pulmonary hypertension, hemolytic anemia, and renal failure: a mitomycin-associated syndome. Chest. 89:1986;608-611.
63. Chang A.Y., Kuebler J.P., Pandya K.J., Israel R.H., Marshall B.C., Torney D.C. Pulmonary toxicity induced by miomycin-C is highly responsive to glucocorticoids. Cancer. 57:1986;2285-2290.
64. Gralla R.J., Kris M.G., Burke M. The influence of the addition of mitomycin to vindesine plus cisplatin in a random-assignment trial in 120 patients with non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol. 5:1986;182.
65. Vansteenkiste J., Vandebroek J., Marien S.et al. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial. Lung Cancer. 13:1995;285-293.
66. Ginsberg R.J., Hill L., Eagan R.et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 86:1983;654-658.
67. Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer. 36:1975;914-925.
68. Coughlin M., Deslauriers J., Beaulieu M.et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg. 40:1985;556-560.
69. Funatsu T., Matsubara Y., Hatakenaka R., Kosaba S., Yasuda Y., Ikeda S. The role of mediastinoscopy biopsy in preoperative assessment of lung cancer. J Thorac Cardiovasc Surg. 104:1992;1688-1695.
70. Kirschner P. Lung cancer: preoperative radiation therapy and surgery. N Y State J Med. 81:1981;339-342.
71. Rodenhuis S., Slebos R.J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52:1992;2665S-2669S.
72. Non-small cell lung cancer collaborative group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 311:1995;899-909.